定义膀胱过度活动症治疗中的疗效。
Defining efficacy in the treatment of overactive bladder syndrome.
作者信息
Shah Sagar, Nitti Victor W
机构信息
Department of Urology, New York University School of Medicine New York, NY.
出版信息
Rev Urol. 2009 Fall;11(4):196-202.
Abstract
Patients seek treatment for overactive bladder syndrome (OAB) due to poor quality of life, and perceived improvement in quality of life (QOL) from medical therapy is multifactorial. Many feel that efficacy/success of medical therapy for OAB should not be linked to improvements in 1 or 2 endpoints, but instead should be linked to patient expectation and QOL improvement. Ideally, once patient-centered goals are defined, outcomes should be correlated with relief of symptom(s), patient satisfaction, and goal attainment expectations as a result of treatment.
摘要
患者因生活质量差而寻求治疗膀胱过度活动症（OAB），而医学治疗带来的生活质量（QOL）改善是多因素的。许多人认为，OAB医学治疗的疗效/成功率不应与一两个终点指标的改善相关联，而应与患者期望和生活质量改善相关联。理想情况下，一旦确定了以患者为中心的目标，治疗结果应与症状缓解、患者满意度以及治疗后目标达成期望相关联。
相似文献
1
Defining efficacy in the treatment of overactive bladder syndrome.定义膀胱过度活动症治疗中的疗效。
Rev Urol. 2009 Fall;11(4):196-202.
2
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).一项前瞻性、双盲、随机、两周期交叉、多中心研究（PREFER）显示，米拉贝隆和托特罗定治疗膀胱过度活动症患者的患者报告结局。
Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0.
3
Treatments for overactive bladder: focus on pharmacotherapy.膀胱过度活动症的治疗：聚焦药物治疗。
J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8.
4
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.索利那新对伴有严重膀胱过度活动症（OAB）症状患者的日记记录和患者报告的急迫性的影响。
Curr Med Res Opin. 2010 Oct;26(10):2277-85. doi: 10.1185/03007995.2010.509582.
5
Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms.患者报告目标达成测量的临床价值：下尿路症状患者自我评估目标达成（SAGA）问卷的全球发展。
Neurourol Urodyn. 2014 Jan;33(1):90-4. doi: 10.1002/nau.22377. Epub 2013 Feb 19.
6
Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis.2 型糖尿病患者膀胱过度活动症症状严重程度、困扰、寻求帮助行为和生活质量：路径分析。
Health Qual Life Outcomes. 2018 Jan 2;16(1):1. doi: 10.1186/s12955-017-0829-z.
7
Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome.随机对照试验中经皮刺激比目鱼肌神经与经皮刺激治疗特发性逼尿肌过度活动症的疗效：患者报告结局。
Neurourol Urodyn. 2021 Jan;40(1):295-302. doi: 10.1002/nau.24554. Epub 2020 Oct 29.
8
Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.富马酸非索罗定 8 毫克优于 4 毫克，可减少膀胱过度活动症患者的急迫性尿失禁发作：随机、双盲、安慰剂对照的 EIGHT 试验结果。
BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.
9
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).米拉贝隆作为索利那新治疗膀胱过度活动症患者的“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）。
BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23.
10
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.用托特罗定治疗的膀胱过度活动症患者症状改善与膀胱状况、症状困扰及健康相关生活质量的患者评估之间的关系。
Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.
引用本文的文献
1
Barriers and facilitators to overactive bladder therapy adherence.膀胱过度活动症治疗依从性的障碍和促进因素。
Neurourol Urodyn. 2022 Nov;41(8):1983-1992. doi: 10.1002/nau.24936. Epub 2022 May 5.
2
Updating the evidence on drugs to treat overactive bladder: a systematic review.更新治疗膀胱过度活动症药物的证据：一项系统评价
Int Urogynecol J. 2019 Oct;30(10):1603-1617. doi: 10.1007/s00192-019-04022-8. Epub 2019 Jul 25.
3
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).一项前瞻性、双盲、随机、两周期交叉、多中心研究（PREFER）显示，米拉贝隆和托特罗定治疗膀胱过度活动症患者的患者报告结局。
Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0.
4
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).一项前瞻性、双盲、随机、两阶段交叉、多中心研究，旨在评估米拉贝隆与托特罗定在膀胱过度活动症患者中的耐受性及患者偏好（PREFER研究）。
Int Urogynecol J. 2018 Feb;29(2):273-283. doi: 10.1007/s00192-017-3377-5. Epub 2017 Jun 15.
5
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.米拉贝隆对膀胱过度活动症患者相关结局的影响：使用三项随机III期试验的汇总数据进行事后相关性分析和应答者分析的结果
Qual Life Res. 2015 Jul;24(7):1719-27. doi: 10.1007/s11136-014-0904-4. Epub 2015 Feb 17.
6
Overactive bladder after female genital mutilation/cutting (FGM/C) type III.女性生殖器切割术（FGM/C）III型后的膀胱过度活动症
BMJ Case Rep. 2013 Oct 4;2013:bcr2012008155. doi: 10.1136/bcr-2012-008155.
7
European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder.膀胱过度活动症患者自我评估目标达成（SAGA）问卷的欧洲内容效度验证
Int Urogynecol J. 2013 Sep;24(9):1529-36. doi: 10.1007/s00192-012-2039-x. Epub 2013 Apr 9.
8
A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms.患者报告结局的定性研究：下尿路症状案例。
Nurs Res. 2012 Jul-Aug;61(4):283-90. doi: 10.1097/NNR.0b013e318251d8f6.
9
Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?患者报告的结果以及膀胱过度活动症中尿参数的不同测量方法：我们应该测量什么？
Int Urogynecol J. 2012 Feb;23(2):179-92. doi: 10.1007/s00192-011-1526-9. Epub 2011 Oct 20.
本文引用的文献
1
Patient-reported reasons for discontinuing overactive bladder medication.患者报告的停止治疗膀胱过度活动症的原因。
BJU Int. 2010 May;105(9):1276-82. doi: 10.1111/j.1464-410X.2009.09036.x. Epub 2009 Nov 12.
2
Extended-release trospium chloride improves quality of life in overactive bladder.盐酸托特罗定控释片改善膀胱过度活动症患者的生活质量。
Value Health. 2010 Mar-Apr;13(2):251-7. doi: 10.1111/j.1524-4733.2009.00652.x. Epub 2009 Oct 8.
3
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.经皮/局部膀胱过度活动症治疗的进展及其相对于口服治疗的优势。
Rev Urol. 2009 Winter;11(1):1-6.
4
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.灵活剂量非索罗定对膀胱过度活动症症状及治疗满意度的影响：一项开放标签研究。
Int J Clin Pract. 2009 Apr;63(4):560-7. doi: 10.1111/j.1742-1241.2009.02035.x.
5
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.氯化奥昔布宁外用凝胶治疗膀胱过度活动症的疗效与安全性：一项随机、双盲、安慰剂对照、多中心研究。
J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.
6
The effects of reformulation: improved therapeutic index.重新配方的效果：提高治疗指数。
Curr Urol Rep. 2008 Nov;9(6):465-71. doi: 10.1007/s11934-008-0080-6.
7
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.对于对先前的缓释抗毒蕈碱疗法表示不满的膀胱过度活动症患者，使用达非那新进行治疗。
Int J Clin Pract. 2008 Nov;62(11):1664-74. doi: 10.1111/j.1742-1241.2008.01893.x. Epub 2008 Sep 22.
8
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.达非那新治疗对患者生活质量的长期益处：一项为期2年的延长期研究结果
Neurourol Urodyn. 2008;27(6):540-7. doi: 10.1002/nau.20620.
9
Impact of fesoterodine on quality of life: pooled data from two randomized trials.非索罗定对生活质量的影响：两项随机试验的汇总数据
BJU Int. 2008 Jul;102(1):56-61. doi: 10.1111/j.1464-410X.2008.07710.x.
10
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.在一个地区性管理式医疗计划中，长效和速释型膀胱过度活动症药物的持续用药率、依从率及换药率。
J Manag Care Pharm. 2008 Apr;14(3):291-301. doi: 10.18553/jmcp.2008.14.3.291.
Zotero 插件